Načítá se...
Progression after Immunotherapy for Fibrolamellar Carcinoma
BACKGROUND: Fibrolamellar carcinoma (FLC) is a rare malignancy of the liver that differs from typical hepatocellular carcinoma (HCC) in several aspects such as the absence of underlying liver disease and occurrence in younger patients. Even though the survival rates in FLC are slightly better than i...
Uloženo v:
| Vydáno v: | Visc Med |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
S. Karger AG
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6597907/ https://ncbi.nlm.nih.gov/pubmed/31312648 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000497464 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|